0.8854  -0.105 (-10.57%)		03-10 16:00
Open: 0.96 High: 0.9905 Volume: 224,414		Pre. Close: 0.99 Low: 0.885 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	1.74	1-year :	2.24
Resists	First :	1.49	Second :	1.91
Pivot price	0.99
Supports	First :	0.8	Second :	0.66
MAs	MA(5) :	0.91	MA(20) :	1.04
	MA(100) :	1.91	MA(250) :	3.94
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	33.5	D(3) :	25.7
RSI	RSI(14): 35.6
52-week	High :	13.62	Low :	0.8

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SHPH ] has closed above bottom band by 17.7%. Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.99 - 1	1 - 1
Low:	0.87 - 0.88	0.88 - 0.88
Close:	0.88 - 0.89	0.89 - 0.89

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Tue, 10 Mar 2026
Shuttle Pharmaceuticals Announces Public Equity Offering for Expansion - TipRanks

Tue, 10 Mar 2026
Shuttle Pharmaceuticals Prices $3.5 Million Equity Offering; Engages E.F. Hutton as Agent - TradingView

Fri, 06 Mar 2026
Shuttle Pharmaceuticals raises $3.5M in public offering - Investing.com Nigeria

Fri, 06 Mar 2026
Shuttle Pharmaceuticals Announces $3.5 Million Public Offering - TMX Newsfile

Fri, 06 Mar 2026
AI drug discovery firm Shuttle Pharma raises $3.5M in public offering - Stock Titan

Tue, 20 Jan 2026
Shuttle Pharma Rockets Over 100% As AI Drug Discovery Gains Attention - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	3 (M)
Held by Insiders	1.59e+006 (%)
Held by Institutions	1.9 (%)
Shares Short	274 (K)
Shares Short P.Month	0 (K)

EPS	-1.09e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-323.3 %
Return on Equity (ttm)	-27 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	298.61
EBITDA (p.s.)	0
Qtrly Earnings Growth	-3.5 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0.46

Dividend	0
Forward Dividend	73190
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.